https://www.selleckchem.com/pr....oducts/tinengotinib.
36% improvement in vessel diameter over single-agent therapy (median PIIR group 1, 10.5% [IQR, 5.3-21.1%] vs group 2, 34.9% [IQR, 21.4-66.0%]; p less then 0.0001). In the adjusted multivariate logistic regression, the use of multiple-agent therapy was associated with a better functional outcome at discharge (OR 0.15, 95% CI [0.04-0.55]; p less then 0.01) and at 90-day follow-up (OR 0.20, 95% CI [0.05-0.77]; p less then 0.05) when compared to single-agent therapy. Conclusion In this study, we found that patients treated for cerebral
Like
Comment
Share
